Humana Braces as CMS Proposes 0.9% Medicare Advantage Payment Increase
- CMS proposal largely freezes MA payment growth, immediately pressuring Humana's plan design and networks.
- Humana must choose between preserving benefits or raising premiums and narrowing formularies to remain solvent.
- Even modest enrollment shifts can change Humana's network leverage, clinical investments, care coordination and drug access.
Humana braces as CMS proposal pins Medicare Advantage payments near flat
Humana and its peers face immediate pressure from a Centers for Medicare and Medicaid Services (CMS) proposal that largely freezes Medicare Advantage (MA) payment growth, a move that reshapes plan design and network decisions as beneficiaries shop coverage during the current short open-enrollment window. CMS proposes a 0.9% increase in MA payment rates for 2027 versus 2026 — about $700 million in payments to plans — far below industry expectations of roughly 4%–6%. Insurers warn the smaller update could force benefit trimming or market exits as firms reprice premiums and reassess provider networks.
The proposal matters for Humana because CMS rates determine how much insurers can offer in benefits and whether they can sustain broad networks, supplemental services and drug coverage on competitive premiums. Medicare Advantage enrollment continues to grow, with KFF reporting that 54% of Medicare beneficiaries — about 34.1 million people in 2025 — are in MA plans, increasing the stakes for large national firms that rely on scale. In this environment, Humana must weigh preserving benefits against raising premiums or narrowing formularies to keep plans solvent and attractive to members.
Heightened competition amplifies the risk of membership churn that affects plan-level financials and patient access. UnitedHealthcare signals potential losses of 1.3 million to 1.4 million MA members in 2026 as beneficiaries shop plans, showing how quickly market share can shift when payment policy changes. For Humana, even modest enrollment flows can alter network leverage and clinical program investments, with downstream effects on care coordination, provider contracts and consumer access to particular drugs or specialists.
Regulatory tweaks on Part D and additional MA rules add complexity
CMS also proposes other Part D and MA policy changes alongside the payment update, prompting insurers to model a range of scenarios for drug formularies and benefit design. Industry groups and analysts tell media outlets such as CNBC that these simultaneous moves heighten the chance insurers narrow offerings or exit less profitable counties.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

